By reviewing the data and tweets, can we predict if the closing price of $amgn will go upwards or downwards at 2017-07-14? Please indicate either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-06-29,1.1,1.2,-0.9,-0.9,-0.9,0.1,-1.3,-2.5,-3.6,-4.9,-5.7
2017-06-30,0.8,1.2,-0.1,-0.2,-0.2,0.3,-0.6,-1.9,-3.0,-4.3,-5.3
2017-07-03,-0.1,0.9,-0.1,0.3,0.3,-0.2,-0.5,-2.0,-2.9,-4.2,-5.3
2017-07-05,-0.9,0.1,-1.3,0.8,0.8,-0.6,-0.8,-2.4,-3.3,-4.5,-5.7
2017-07-06,0.8,1.1,-0.2,-1.5,-1.5,0.6,0.7,-0.7,-1.6,-2.7,-3.9
2017-07-07,0.1,0.3,-0.5,-0.2,-0.2,0.6,0.7,-0.2,-1.2,-2.2,-3.4
2017-07-10,-0.4,0.2,-0.7,0.4,0.4,0.2,0.2,-0.3,-1.4,-2.3,-3.5
2017-07-11,0.5,0.6,-0.7,0.7,0.7,-0.4,-0.4,-0.6,-1.8,-2.7,-3.8
2017-07-12,0.3,0.6,-0.3,-0.0,-0.0,-0.5,-0.3,-0.3,-1.5,-2.3,-3.4
2017-07-13,-1.0,0.7,-1.1,1.0,1.0,-1.1,-1.2,-1.2,-2.2,-3.0,-4.0

2017-06-29: fda approves AT_USER test kra/nras (56 variants) to inform pt selection for $amgn's vectibix #precisionmedicine |third time's a charm for $admp  #fda $chrs $amgn $itek $psdv $cara $rigl #neartermcatal
2017-06-30: oppenheimer holdings, inc. reiterates ¡°outperform¡± rating for amgen inc. $amgn |amgen inc. $amgn given outperform rating at oppenheimer holdings, inc. |amgen inc. $amgn given outperform rating at op
2017-07-01: {new video} biotech analysis + trade ideas: $ibb $xbi $nbi $celg $amgn $agn $gild $regn --&gt;  |a head above the rest? drugmakers face off in migraine market  $lly $amgn $aldr $teva|#amgen's colorect
2017-07-02: $amgn sum put vol=1,084 sum call vol=450 putcallratio=2.41 expiration 07/07/2017 .  |rt AT_USER AT_USER AT_USER $amgn calls it #repatha !|AT_USER AT_USER $amgn calls it #repatha !|stocks to watch this
2017-07-03: what happened to $amgn ?? |$amzn $amgn $csco $msft $aapl all have weird marks|$amgn sum put vol=566 sum call vol=667 putcallratio=0.85 expiration 07/07/2017 .  |anyone seeing whacky quotes $aapl $amzn
2017-07-04: #amgen two cancer drug prices have already been hiked by 8% this year. read more:  $amgn|rt AT_USER cgrp drugs could represent a step-change in the treatment of migraine  $lly $amgn $aldr $teva|$amgn 
2017-07-05: $amgn looking healthy for possible ath test soon. |$fgen all time high! who was selling early this yr after the fantastic p3 chinese results were announced. the next $amgn in the making!|rt seekingalp
2017-07-06: rt AT_USER amgen, teva hikes show pharma can't blame rebates for all price increases: analyst  $amgn $teva|almost all my big winners last few years same playbook: little to no revenue growth sell debt
2017-07-07: follow #nasdaq 100 traders &amp; track their tweets under one watchlist $amgn $qcom  |rt AT_USER more cancer drug price hikes, incl. $amgn hiking blincyto by 8% in '17 = $14k incr. per treatment cours
2017-07-08: $chrs loses another partner on its enbrel biosimilar  $amgn|AT_USER and why commit bank to $arwr &amp; not dictate numerous terms~to a cash poor company (at the time). i agree¡­ |AT_USER yes, seemingl
2017-07-09: watching--$adbe, $amgn, $avgo &amp; $ba for breakout retest.  #gst|AT_USER AT_USER AT_USER top of thread: 4/26 sean harper $amgn r&amp;d opined, "collaboration has b¡­ |household names that have becom
2017-07-10: rt AT_USER jefferies pt's $acor $22, $fgen $50, $amgn $195, $vrtx $155, $icpt $155, $axon $40, $prta $100, $once $85|novartis' ( $nvs ) cosentyx superior to stelara in psoriasis study + news on $amgn 
2017-07-11: icymi: fda says evidence supports amgen, mylan biosimilars of roche cancer drugs  #fda #odac $amgn $myl #biosimilars|#fda grants full approval of $amgn's #blincyto in relapsed/refractory b-cell precur
2017-07-12: $amgn max pain = 172.50. maturity = 07/14/2017. previous close = 173.32.   |rt AT_USER will keep posting about $fgen story can be very confusing but all you need to know is roxadustat is about to rumb
2017-07-13: $amgn max pain is 172.50 for maturity 07/14/2017. prev close = 173.27.   |rt AT_USER $ibb $amgn $celg $gild break out. |$amgn gap fill special, if they stay w/ biotech this name needs to be on your ra
Answer:
By reviewing the data and tweets, can we predict if the closing price of $amgn will go upwards or downwards at 2017-07-14? Please indicate either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-06-29,1.1,1.2,-0.9,-0.9,-0.9,0.1,-1.3,-2.5,-3.6,-4.9,-5.7
2017-06-30,0.8,1.2,-0.1,-0.2,-0.2,0.3,-0.6,-1.9,-3.0,-4.3,-5.3
2017-07-03,-0.1,0.9,-0.1,0.3,0.3,-0.2,-0.5,-2.0,-2.9,-4.2,-5.3
2017-07-05,-0.9,0.1,-1.3,0.8,0.8,-0.6,-0.8,-2.4,-3.3,-4.5,-5.7
2017-07-06,0.8,1.1,-0.2,-1.5,-1.5,0.6,0.7,-0.7,-1.6,-2.7,-3.9
2017-07-07,0.1,0.3,-0.5,-0.2,-0.2,0.6,0.7,-0.2,-1.2,-2.2,-3.4
2017-07-10,-0.4,0.2,-0.7,0.4,0.4,0.2,0.2,-0.3,-1.4,-2.3,-3.5
2017-07-11,0.5,0.6,-0.7,0.7,0.7,-0.4,-0.4,-0.6,-1.8,-2.7,-3.8
2017-07-12,0.3,0.6,-0.3,-0.0,-0.0,-0.5,-0.3,-0.3,-1.5,-2.3,-3.4
2017-07-13,-1.0,0.7,-1.1,1.0,1.0,-1.1,-1.2,-1.2,-2.2,-3.0,-4.0

2017-06-29: fda approves AT_USER test kra/nras (56 variants) to inform pt selection for $amgn's vectibix #precisionmedicine |third time's a charm for $admp  #fda $chrs $amgn $itek $psdv $cara $rigl #neartermcatal
2017-06-30: oppenheimer holdings, inc. reiterates ¡°outperform¡± rating for amgen inc. $amgn |amgen inc. $amgn given outperform rating at oppenheimer holdings, inc. |amgen inc. $amgn given outperform rating at op
2017-07-01: {new video} biotech analysis + trade ideas: $ibb $xbi $nbi $celg $amgn $agn $gild $regn --&gt;  |a head above the rest? drugmakers face off in migraine market  $lly $amgn $aldr $teva|#amgen's colorect
2017-07-02: $amgn sum put vol=1,084 sum call vol=450 putcallratio=2.41 expiration 07/07/2017 .  |rt AT_USER AT_USER AT_USER $amgn calls it #repatha !|AT_USER AT_USER $amgn calls it #repatha !|stocks to watch this
2017-07-03: what happened to $amgn ?? |$amzn $amgn $csco $msft $aapl all have weird marks|$amgn sum put vol=566 sum call vol=667 putcallratio=0.85 expiration 07/07/2017 .  |anyone seeing whacky quotes $aapl $amzn
2017-07-04: #amgen two cancer drug prices have already been hiked by 8% this year. read more:  $amgn|rt AT_USER cgrp drugs could represent a step-change in the treatment of migraine  $lly $amgn $aldr $teva|$amgn 
2017-07-05: $amgn looking healthy for possible ath test soon. |$fgen all time high! who was selling early this yr after the fantastic p3 chinese results were announced. the next $amgn in the making!|rt seekingalp
2017-07-06: rt AT_USER amgen, teva hikes show pharma can't blame rebates for all price increases: analyst  $amgn $teva|almost all my big winners last few years same playbook: little to no revenue growth sell debt
2017-07-07: follow #nasdaq 100 traders &amp; track their tweets under one watchlist $amgn $qcom  |rt AT_USER more cancer drug price hikes, incl. $amgn hiking blincyto by 8% in '17 = $14k incr. per treatment cours
2017-07-08: $chrs loses another partner on its enbrel biosimilar  $amgn|AT_USER and why commit bank to $arwr &amp; not dictate numerous terms~to a cash poor company (at the time). i agree¡­ |AT_USER yes, seemingl
2017-07-09: watching--$adbe, $amgn, $avgo &amp; $ba for breakout retest.  #gst|AT_USER AT_USER AT_USER top of thread: 4/26 sean harper $amgn r&amp;d opined, "collaboration has b¡­ |household names that have becom
2017-07-10: rt AT_USER jefferies pt's $acor $22, $fgen $50, $amgn $195, $vrtx $155, $icpt $155, $axon $40, $prta $100, $once $85|novartis' ( $nvs ) cosentyx superior to stelara in psoriasis study + news on $amgn 
2017-07-11: icymi: fda says evidence supports amgen, mylan biosimilars of roche cancer drugs  #fda #odac $amgn $myl #biosimilars|#fda grants full approval of $amgn's #blincyto in relapsed/refractory b-cell precur
2017-07-12: $amgn max pain = 172.50. maturity = 07/14/2017. previous close = 173.32.   |rt AT_USER will keep posting about $fgen story can be very confusing but all you need to know is roxadustat is about to rumb
2017-07-13: $amgn max pain is 172.50 for maturity 07/14/2017. prev close = 173.27.   |rt AT_USER $ibb $amgn $celg $gild break out. |$amgn gap fill special, if they stay w/ biotech this name needs to be on your ra
Answer:+Rise